{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T11:00:05Z","timestamp":1761390005301,"version":"build-2065373602"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some injectable medicines introduced recently allow patients with multiple myeloma (MM) to receive their chemotherapy at home. This study aimed at describing adult patients with MM receiving injectable chemotherapy via hospital\u2010at\u2010home (HAH) services and outpatient hospital units (OHUs) in metropolitan France in 2019 and 2020, analyzing the factors influencing HAH use, and evaluating the geographic variations and the evolution over time of HAH use by these patients during the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Real\u2010world data from the French Hospital Discharge Database (PMSI) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 2169\/9278\u00a0patients (23.4%) received at least one HAH chemotherapy injection. These patients were diagnosed more recently (mean\u00a0\u00b1\u00a0standard deviation\u00a0= 25.1\u00a0\u00b1\u00a019.6 vs. 31.6\u00a0\u00b1\u00a021.8\u00a0months), and lived in larger and wealthier cities (59,000 vs. 41,000\u00a0inhabitants; \u20ac23,300\u00a0\u00b1\u00a0\u20ac5300 vs. \u20ac21,700\u00a0\u00b1\u00a0\u20ac4100) and closer to their follow\u2010up hospital (18.7\u00a0\u00b1\u00a018.4 vs. 31.3\u00a0\u00b1\u00a031.2\u00a0km) than patients exclusively treated in OHUs (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Receiving bortezomib and carfilzomib, and the first chemotherapy dose in 2020, were the most significant factors associated with HAH use (odds ratio [95%\u00a0confidence interval]: 6.12 [5.40\u20136.96], 2.01 [1.69\u20102.39], and 1.81 [1.57\u20132.09], respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). HAH use increased between 2019 and 2020 (patients, +23%; administrative departments, +25%), likely related to the COVID\u201019 pandemic. However, HAH use remained limited overall and exhibited inter\u2010regional variability. Infection\u2010related hospitalizations remained stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Receiving chemotherapy injections at home is feasible and safe, but further development and equitable access are essential to enhance patients\u2019 quality of life and reduce costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70144","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:14:17Z","timestamp":1757603657000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Hospital\u2010at\u2010Home Services for Injectable Chemotherapy for Patients With Multiple Myeloma in France in 2019 and 2020: A Real\u2010World Nationwide Study Based on the French Hospital Discharge Database"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5904-1286","authenticated-orcid":false,"given":"Laure","family":"Vincent","sequence":"first","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie clinique CHU de Montpellier H\u00f4pital Saint Eloi  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-8539","authenticated-orcid":false,"given":"Anne\u2010Sophie","family":"Jannot","sequence":"additional","affiliation":[{"name":"Banque Nationale de Donn\u00e9es Maladies Rares (BNDMR), AP\u2010HP  Paris France"},{"name":"HeKA, INRIA Paris, Inserm, Centre de Recherche des Cordeliers Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakima","family":"Mechiche","sequence":"additional","affiliation":[{"name":"Amgen SAS  Courbevoie France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulysse","family":"Rodts","sequence":"additional","affiliation":[{"name":"KanopyMed  Clapiers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4636-7361","authenticated-orcid":false,"given":"Ga\u00eblle","family":"D\u00e9sam\u00e9ricq","sequence":"additional","affiliation":[{"name":"Amgen SAS  Courbevoie France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46"},{"key":"e_1_2_13_3_1","unstructured":"Estimates of Cancer Incidence and Mortality in 2022 For All Countries European Cancer Information System (ECI). accessed July 1 2025 https:\/\/ecis.jrc.ec.europa.eu\/explorer.php?$0\u20100$1\u2010All$2\u2010All$4\u20101 2$3\u201051$6\u20100 85$5\u20102022 2022$7\u20107$CEstByCountry$X0_8\u20103$X0_19\u2010AE27$X0_20\u2010No$CEstBySexByCountry$X1_8\u20103$X1_19\u2010AE27$X1_\u20101\u20101$CEstByIndiByCountry$X2_8\u20103$X2_19\u2010AE27$X2_20\u2010No$CEstRelative$X3_8\u20103$X3_9\u2010AE27$X3_19\u2010AE27$CEstByCountryTable$X4_19\u2010AE27."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"volume-title":"Estimations Nationales de L'incidence et de la Mortalit\u00e9 par Cancer en France M\u00e9tropolitaine Entre 1990 et 2018: \u00c9tude \u00e0 Partir Des Registres Des Cancers Du R\u00e9seau Francim","year":"2019","author":"Le Guyader\u2010Peyrou S.","key":"e_1_2_13_6_1"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002493"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.025"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.03.011"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.1065"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4958-5"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3917\/spub.163.0341"},{"key":"e_1_2_13_14_1","unstructured":"Direction de la recherche des \u00e9tudes de l\u2019\u00e9valuation et des statistiques (Drees).Solidarit\u00e9 et Sant\u00e9: Donn\u00e9es de sant\u00e9: anonymat et risque de r\u00e9\u2010identification(DREES 2015) https:\/\/www.casd.eu\/wp\/wp\u2010content\/uploads\/dss64\u20102.pdf."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"e_1_2_13_16_1","unstructured":"R.Core Team \"R: A Language and Environment for Statistical Computing\" (2018) https:\/\/www.R\u2010project.org\/."},{"key":"e_1_2_13_17_1","first-page":"168","article-title":"Disparit\u00e9 d'acc\u00e8s \u00e0 l'hospitalisation \u00e0 Domicile pour les Patients Atteints de My\u00e9lome Multiple Trait\u00e9s par Chimioth\u00e9rapie Injectable en France Une \u00c9tude \u00e0 Partir de la Base Du Programme de M\u00e9dicalisation Des Syst\u00e8mes d'information","volume":"27","author":"Rodts U.","year":"2021","journal-title":"H\u00e9matologie"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2021.09.012"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2022.09.052"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102478"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2020.04.002"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv563"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3363-3"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01463-9"},{"key":"e_1_2_13_25_1","unstructured":"APM News.HAD: La Croissance D'activit\u00e9 Fr\u00f4le Les 6% En 2023 Mais Avec De Fortes Disparit\u00e9s R\u00e9gionales (infographies) APM News August 30 2024 https:\/\/www.apmnews.com\/depeche\/98678\/413884\/had\u2010la%C2%A0croissance\u2010d\u2010activite\u2010frole\u2010les%C2%A06\u2013en%C2%A02023%2C\u2010mais\u2010avec\u2010de%C2%A0fortes\u2010disparites\u2010regionales\u2010%28infographies%29."},{"key":"e_1_2_13_26_1","unstructured":"Cercle de R\u00e9flexion en Immuno\u2010oncologie IMMUNOTH\u00c9RAPIE \u00c0 DOMICILE Quels Enjeux Et Quel Mod\u00e8le Pour Le D\u00e9veloppement De L'hospitalisation \u00e0 Domicile Pour Les Patients Atteints De Cancer?(2023) accessed Aug 1 2025 https:\/\/www.crio\u2010immunotherapie.fr\/."},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2021.09.014"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4266"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196596"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2015.05.001"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:53:41Z","timestamp":1761389621000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/jha2.70144"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70144","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"type":"print","value":"2688-6146"},{"type":"electronic","value":"2688-6146"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"2025-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70144"}}